视频：Øystein Soug 谈领导 Oncoinvent 与 α 发射放射性药物 Radspherin 开发
Video: Leading the Alpha Charge – with Øystein Soug
Øystein Soug 现任 Oncoinvent 负责人，领导 α 发射放射性药物 Radspherin 的开发，该药不依赖受体靶向，直接注入腹腔以治疗腹腔转移癌。他回顾了参与 Xofigo 上市的经验，并指出生产与供应链仍是放射性药物最难解决的问题。他还谈及新同位素、给药方式和联合策略的可能性，以及奥斯陆作为放射性药物中心的兴起。
From the Norwegian Air Force to alpha-emitting radiopharmaceuticals, Øystein Soug has taken the unconventional route to biotech leadership
10/28/2026 1 min read Video
Share
Øystein Soug’s route to biotech leadership was anything but conventional: military training, finance roles in Russia and China, and more than a decade as a CFO before biotechnology offered an unexpected change of direction.
Today, Soug leads Oncoinvent and the development of Radspherin, a receptor-independent alpha-emitting radiopharmaceutical designed to treat cancers that have spread to the abdominal cavity. Rather than relying on biological targeting, the therapy is delivered directly into the peritoneum – an approach intended to concentrate radiation around residual cancer cells while limiting exposure elsewhere in the body.
Soug discusses the lessons learned from helping bring Xofigo to market, why manufacturing and supply chains remain radiopharma’s stubbornest challenges, and the possibilities created by new isotopes, delivery methods, and combination strategies. He also reflects on Oslo’s emergence as a radiopharmaceutical hub and the everyday realities of leadership: solving problems, making decisions, and putting in the hours.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
来源：The Medicine Maker · themedicinemaker.com